![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina
All-trans retinoic acid (ATRA) induces differentiation of promyelocytic leukemia cells, but the mechanisms by which cellular differentiation leads to apoptosis are not well understood. Studies were done to address the question whether ATRA-induced apoptosis is a consequence of destabilization of bcl-2 mRNA and decreased cellular levels of the anti-apoptotic protein, bcl-2. ATRA induced differentiation of HL-60 cells along the granulocytic pathway within 48 h. The half-lives of bcl-2 mRNA in HL-60 cells incubated with ATRA for 48 or 72 h were reduced to 39 and 7% of the corresponding untreated control values, respectively. Cellular differentiation was accompanied by down-regulation of the cytoplasmic levels of nucleolin, a bcl-2 mRNA-stabilizing protein. Binding of a bcl-2 mRNA instability element (AU-rich element-1) to nucleolin in S100 extracts from ATRA-treated cells was decreased to 15% of control within 72 h. The decay of 5' capped, polyadenylated bcl-2 mRNA transcripts containing ARE-1 was more rapid in S100 extracts from ATRA-treated cells compared with untreated cells. However, when recombinant nucleolin was added to extracts of ATRA-treated cells, the rate of bcl-2 mRNA decay was similar to the rate in extracts of untreated cells. These results provide evidence that ATRA-induced apoptosis is a consequence of cellular differentiation, which leads to nucleolin down-regulation and bcl-2 mRNA instability.
Address correspondence to: Daniel J. Fernandes, Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 173 Ashley Avenue, P.O. Box 250509, Charleston, SC 29425. E-mail: fernand{at}musc.edu.
This article has been cited by other articles:
|
|
 |
|
  S. Soundararajan, W. Chen, E. K. Spicer, N. Courtenay-Luck, and D. J. Fernandes The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer Cells Cancer Res., April 1, 2008; 68(7): 2358 - 2365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Xie, I. Kobayashi, T. Kiyoshima, H. Yamaza, J.-y. Honda, K. Takahashi, N. Enoki, A. Akamine, and H. Sakai Functional Implication of Nucleolin in the Mouse First Molar Development J. Biol. Chem., August 10, 2007; 282(32): 23275 - 23283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Grinstein, Y. Du, S. Santourlidis, J. Christ, M. Uhrberg, and P. Wernet Nucleolin Regulates Gene Expression in CD34-positive Hematopoietic Cells J. Biol. Chem., April 27, 2007; 282(17): 12439 - 12449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Otake, S. Soundararajan, T. K. Sengupta, E. A. Kio, J. C. Smith, M. Pineda-Roman, R. K. Stuart, E. K. Spicer, and D. J. Fernandes Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA Blood, April 1, 2007; 109(7): 3069 - 3075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Ireson and L. R. Kelland Discovery and development of anticancer aptamers Mol. Cancer Ther., December 1, 2006; 5(12): 2957 - 2962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-L. Wu, C. Dudognon, E. Nguyen, J. Hillion, F. Pendino, I. Tarkanyi, J. Aradi, M. Lanotte, J.-H. Tong, G.-Q. Chen, et al. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths J. Cell Sci., July 1, 2006; 119(13): 2797 - 2806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Jiang, X.-S. Xu, and J. E. Russell A Nucleolin-Binding 3' Untranslated Region Element Stabilizes {beta}-Globin mRNA In Vivo. Mol. Cell. Biol., March 1, 2006; 26(6): 2419 - 2429. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
